Insights to Impact:
A Selection of Our Recent Work

A leading mRNA manufacturing CDMO had six offering configurations for potential launch in the mRNA manufacturing space. Carl's team produced the sequenced launch path that the commercial and product leadership teams moved forward with.

A PE-backed life sciences tools company needed to decide whether to greenlight development of a next-generation integrated platform. Carl's team ran demand validation across forty prospective buyers and delivered a go recommendation grounded in quantitative evidence, competitive positioning, and internal feasibility.

A leading European healthcare PE firm had eighteen days to a final bid on a cell therapy reagents supplier. Carl's team produced a three-dimensional scenario framework that gave the deal team a full investment committee view with a week to spare.

A Series B venture-backed cell engineering platform company needed a prioritized entry path across three customer segments and four candidate commercial models. Carl's team produced the sequenced entry path the company moved on within weeks of the final readout.

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy